Endocyte (ECYT) 10-Q 8 Aug 14 2014 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Jun. 30, 2014	Jul. 31, 2014
Document Information [Line Items]	'	'
Entity Registrant Name	'ENDOCYTE INC	'
Entity Central Index Key	'0001235007	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Trading Symbol	'ECYT	'
Entity Common Stock, Shares Outstanding	'	41,550,956
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Period Focus	'Q2	'
Document Fiscal Year Focus	'2014	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$31,568,503	$52,846,940
Short-term investments	89,533,740	70,434,148
Receivables	5,278,563	6,353,180
Prepaid expenses	1,482,814	3,200,924
Other assets	810,983	496,338
Total current assets	128,674,603	133,331,530
Long-term investments	98,097,613	25,571,659
Property and equipment, net	4,162,488	3,839,426
Other noncurrent assets	11,194	114,961
Total assets	230,945,898	162,857,576
Current liabilities:	'	'
Accounts payable	3,490,647	5,435,473
Accrued wages and benefits	2,173,381	3,065,905
Accrued clinical trial expenses	7,381,758	3,728,015
Accrued expenses	2,168,692	1,668,944
Deferred revenue	50,000	59,746,952
Current portion of other liabilities	15,729	18,168
Total current liabilities	15,280,207	73,663,457
Other liabilities, net of current portion	27,782	33,458
Deferred revenue, net of current portion	906,944	931,940
Total liabilities	16,214,933	74,628,855
Stockholders’ equity:	'	'
Common stock: $0.001 par value, 100,000,000 shares authorized; 36,155,509 and 41,549,477 shares issued and outstanding at December 31, 2013 and June 30, 2014	41,550	36,156
Additional paid-in capital	369,437,135	262,060,590
Accumulated other comprehensive income	-38,187	56,691
Retained deficit	-154,709,533	-173,924,716
Total stockholders’ equity	214,730,965	88,228,721
Total liabilities and stockholders’ equity	$230,945,898	$162,857,576

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	41,549,477	36,155,509
Common stock, shares outstanding	41,549,477	36,155,509

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenue:	'	'	'	'
Collaboration revenue	$49,168,527	$16,483,278	$66,437,178	$30,997,422
Operating expenses:	'	'	'	'
Research and development	18,989,933	18,607,025	31,976,696	30,865,664
General and administrative	7,968,211	6,211,429	15,469,605	12,467,431
Total operating expenses	26,958,144	24,818,454	47,446,301	43,333,095
Income (loss) from operations	22,210,383	-8,335,176	18,990,877	-12,335,673
Other income (expense), net:	'	'	'	'
Interest income	169,026	126,616	253,714	266,353
Interest expense	-431	-669	-815	-1,443
Other income (expense), net	-22,336	-18,247	-28,593	-18,384
Net income (loss)	22,356,642	-8,227,476	19,215,183	-12,089,147
Net income (loss) per share:	'	'	'	'
Basic (in dollars per share)	$0.54	($0.23)	$0.50	($0.34)
Diluted (in dollars per share)	$0.52	($0.23)	$0.47	($0.34)
Items included in other comprehensive loss:	'	'	'	'
Unrealized loss on foreign currency translation	-29,010	-21,880	-28,500	-21,250
Unrealized loss on available-for-sale securities	-57,521	-98,837	-66,378	-139,051
Other comprehensive loss	-86,531	-120,717	-94,878	-160,301
Comprehensive income (loss)	$22,270,111	($8,348,193)	$19,120,305	($12,249,448)
Weighted-average number of common shares used in net income (loss) per share calculation:	'	'	'	'
Basic (in shares)	41,398,251	35,991,402	38,810,473	35,961,002
Diluted (in shares)	43,196,754	35,991,402	40,861,295	35,961,002

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Retained Earnings [Member]
Balances at Dec. 31, 2013	$88,228,721	$36,156	$262,060,590	$56,691	($173,924,716)
Balances (in shares) at Dec. 31, 2013	'	36,155,509	'	'	'
Exercise of stock options	580,872	187	580,685	0	0
Exercise of stock options (in shares)	'	186,800	'	'	'
Stock-based compensation	4,705,012	0	4,705,012	0	0
Employee stock purchase plan	191,078	32	191,046	0	0
Employee Stock Purchase Plan(shares)	'	32,168	'	'	'
Issuance of common stock in connection with equity offering	101,904,977	5,175	101,899,802	0	0
Issuance of common stock in connection with equity offering (in shares)	'	5,175,000	'	'	'
Net income	19,215,183	0	0	0	19,215,183
Unrealized loss on foreign currency translation	-28,500	0	0	-28,500	0
Unrealized loss on securities	-66,378	0	0	-66,378	0
Balances (unaudited) at Jun. 30, 2014	$214,730,965	$41,550	$369,437,135	($38,187)	($154,709,533)
Balances (unaudited) (in shares) at Jun. 30, 2014	'	41,549,477	'	'	'

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Operating activities	'	'
Net income (loss)	$19,215,183	($12,089,147)
Adjustments to reconcile net income (loss) to net cash used in operating activities:	'	'
Depreciation	410,505	311,960
Stock-based compensation	4,705,012	2,670,494
Accretion of bond premium	816,529	539,773
Loss on disposal of property and equipment	2,619	1,778
Change in operating assets and liabilities:	'	'
Receivables	759,971	3,181,324
Prepaid expenses and other assets	1,910,782	723,374
Accounts payable	-1,831,743	-808,589
Accrued interest, wages, benefits and other liabilities	3,252,852	766,913
Deferred revenue	-59,721,948	-25,996,587
Net cash used in operating activities	-30,480,238	-30,698,707
Investing activities	'	'
Purchases of property and equipment	-938,174	-472,998
Purchases of investments	-112,097,344	-87,436,680
Proceeds from sale of investments	19,588,892	148,546,204
Net cash provided by (used in) investing activities	-93,446,626	60,636,526
Financing activities	'	'
Proceeds from public offering	101,904,977	0
Proceeds from the exercise of stock options	580,872	303,005
Proceeds from stock purchases under employee stock purchase plan	191,078	0
Net cash provided by financing activities	102,676,927	303,005
Effect of exchange rate	-28,500	-21,250
Net increase (decrease) in cash and cash equivalents	-21,278,437	30,219,574
Cash and cash equivalents at beginning of period	52,846,940	33,996,866
Cash and cash equivalents at end of period	$31,568,503	$64,216,440

Nature_of_Business_and_Organiz

Nature of Business and Organization	6 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	'
	1. Nature of Business and Organization
	Endocyte, Inc. (the “Company”) is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. The Company uses its proprietary technology to create novel small molecule drug conjugates (“SMDCs”), and companion imaging agents. The SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with a highly active drug at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The Company is also developing companion imaging agents for each of its SMDCs that are designed to identify the patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.
	The Company has two wholly-owned subsidiaries, Endocyte Europe B.V. and Endocyte Europe GmbH, which were formed to assist with the administration of applications with the European Commission (“EC”) and commercial pre-launch activities in Europe. The applications were withdrawn in May 2014 and the commercial pre-launch activities in Europe ceased. The Company is currently assessing the future plans for these entities.

Significant_Accounting_Policie

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	2. Significant Accounting Policies
	Basis of Presentation
	The accompanying condensed consolidated financial statements include the accounts of Endocyte, Inc. and its subsidiaries and all intercompany amounts have been eliminated. The condensed consolidated financial statements are prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) for interim financial information to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring accruals and revisions of estimates, considered necessary for a fair presentation of the accompanying condensed consolidated financial statements have been included. Interim results for the three and six  months ended June 30, 2014 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2014 or any other future period. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013. Subsequent events have been evaluated through the date of issuance, which is the same as the date this Form 10-Q is filed with the Securities and Exchange Commission.
	Segment Information
	Operating segments are defined as components of an enterprise engaging in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company performs clinical trials globally and has established a subsidiary in The Netherlands to assist in the administration of filing applications in Europe and a subsidiary in Switzerland for commercial pre-launch activities in Europe. The applications filed in Europe were withdrawn in May 2014 and the pre-launch activities in Europe ceased. All long-lived assets are held in the U.S. The Company views its operations and manages its business in one operating segment.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual amounts could differ from those estimates.
	Cash and Cash Equivalents
	The Company considers cash and all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents consist primarily of money market instruments that are maintained by an investment manager.
	Investments
	Investments consist primarily of investments in U.S. Treasuries, U.S. Government agency obligations and corporate debt securities, which could also include commercial paper, that are maintained by an investment manager. Management determines the appropriate classification of marketable securities at the time of purchase and reevaluates such classification as of each balance sheet date. Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in other comprehensive income. Realized gains and losses and declines in value judged to be other-than-temporary on available-for-sale securities are included in other income. The Company considers and accounts for other-than-temporary impairments according to the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 320, Investments — Debt and Equity Securities (“ASC 320”). The cost of securities sold is based on the specific-identification method. Discounts and premiums on debt securities are amortized to interest income and expense over the term of the security.
	Revenue Recognition
	The Company recognizes revenues from license and collaboration agreements when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the fee is fixed or determinable, and there is reasonable assurance that the related amounts are collectible in accordance with ASC Topic 605, Revenue Recognition (“ASC 605”). The Company’s license and collaboration agreements may contain multiple elements, including grants of licenses to intellectual property rights, agreement to provide research and development services and other deliverables. The deliverables under such arrangements are evaluated under ASC Subtopic 605-25, Multiple-Element Arrangements. Under ASC 605-25, each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting based on whether the deliverable has “stand-alone value” to the customer. The arrangement’s consideration that is fixed or determinable, excluding contingent milestone payments, is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. In general, the consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables.
	Upfront payments for licensing the Company's intellectual property are evaluated to determine if the licensee can obtain stand-alone value from the license separate from the value of the research and development services and other deliverables in the arrangement to be provided by the Company. If at the inception of an arrangement the Company determines that the license does not have stand-alone value separate from the research and development services or other deliverables, the license, services and other deliverables are combined as one unit of account and upfront payments are recorded as deferred revenue in the balance sheet and are recognized in a manner consistent with the final deliverable. Subsequent to the inception of an arrangement, the Company evaluates the remaining deliverables for separation as items in the arrangement are delivered. When stand-alone value is identified, the related consideration is recorded as revenue in the period in which the license or other intellectual property rights are delivered.
	In those circumstances where research and development services or other deliverables are combined with the license, and multiple services are being performed such that a common output measure to determine a pattern of performance cannot be discerned, the Company recognizes amounts received on a straight line basis over the performance period. Such amounts are recorded as collaboration revenue. Any subsequent reimbursement payments, which are contingent upon the Company’s future research and development expenditures, will be recorded as collaboration revenue and will be recognized on a straight-line basis over the performance period using the cumulative catch up method. The costs associated with these activities are reflected as a component of research and development expense in the statements of operations in the period incurred. In the event of an early termination of a collaboration agreement, any deferred revenue is recognized in the period in which all obligations of the Company under the agreement have been fulfilled.
	Milestone payments under collaborative arrangements are triggered either by the results of the Company’s research and development efforts, achievement of regulatory goals or by specified sales results by a third-party collaborator. Milestones related to the Company’s development-based activities may include initiation of various phases of clinical trials and applications and acceptance for product approvals by regulatory agencies. Due to the uncertainty involved in meeting these development-based milestones, the determination is made at the inception of the collaboration agreement whether the development-based milestones are considered to be substantive (i.e. not just achieved through passage of time). In addition, the amounts of the payments assigned thereto are considered to be commensurate with the enhancement of the value of the delivered intellectual property as a result of the Company’s performance. Because the Company’s involvement is necessary to the achievement of development-based milestones, the Company would account for development-based milestones as revenue upon achievement of the substantive milestone events. Milestones related to sales-based activities may be triggered upon events such as first commercial sale of a product or when sales first achieve a defined level. Since these sales-based milestones would be achieved after the completion of the Company’s development activities, the Company would account for the sales-based milestones in the same manner as royalties, with revenue recognized upon achievement of the milestone.
	Royalties based on reported sales of licensed products will be recognized based on contract terms when reported sales are reliably measurable and collectability is reasonably assured. To date, none of the Company's products have been approved and therefore the Company has not earned any royalty revenue from product sales. In territories where the Company and the collaborator will share profit, the revenue will be recorded in the period earned.
	Research and Development Expenses
	Research and development expenses represent costs associated with the ongoing development of SMDCs and companion imaging agents and include salaries, supplies, and expenses for clinical trials. The Company records accruals for clinical trial expenses based on the estimated amount of work completed. The Company monitors patient enrollment levels and related activities to the extent possible through internal reviews, correspondence, and discussions with research organizations. In the event that a clinical trial is terminated early, the Company records, in the period of termination, an accrual for the estimated remaining costs to complete the trial.
	Upfront payments made in connection with business collaborations and research and development arrangements are evaluated under ASC Subtopic 730-20, Research and Development Arrangements. Upfront payments made in connection with business development collaborations are expensed as research and development costs, as the assets acquired do not have alternative future use. Amounts related to future research and development are capitalized as prepaid research and development and are expensed over the service period based upon the level of services provided. As of June 30, 2014, the Company had approximately $0.6 million of capitalized research and development costs included in prepaid expenses and other noncurrent assets.
	Stock-Based Compensation
	The Company accounts for its stock options pursuant to ASC Topic 718, Compensation — Stock Compensation (“ASC 718”), which requires the recognition of the fair value, or calculated value for nonpublic entities, of stock-based compensation in net income. Stock-based compensation consists of stock options, which are granted at exercise prices at or above the fair market value of the Company’s common stock on the dates of grant. The Company has issued performance-based restricted stock units (“PRSUs”) for which stock-based compensation expense will be recognized when the Company determines that it is probable that the performance conditions will be achieved. The Company has also issued service-based restricted stock units (“RSUs”) for which stock-based compensation expense is recognized ratably over the service period. The Company used the calculated value method to measure its stock-based compensation prior to its initial public offering. The Company recognizes compensation cost based on the grant-date value estimated in accordance with the provisions of ASC 718.
	Net Income (Loss) Per Share
	Basic net income (loss) per share is calculated by dividing the net income (loss) attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. For purposes of this calculation, stock options, warrants, PRSUs, RSUs and shares to be purchased under the Company’s 2010 Employee Stock Purchase Plan (“ESPP”) are considered to be common stock equivalents and are only included in the calculation of diluted net income (loss) per share when their effect is dilutive.
	The following tables and discussion provide a reconciliation of the numerator and denominator of the basic and diluted net income (loss) per share computations. The calculation below provides net income (loss), weighted-average common shares outstanding, and the resultant net income (loss) per share on both a basic and diluted basis for the three and six months ended June 30, 2013 and 2014.
	Historical net income (loss) per share
		Three Months Ended June 30,				Six Months Ended June 30,
		2013		2014		2013		2014
	Numerator:
	Net income (loss)	$	-8,227,476	$	22,356,642	$	-12,089,147	$	19,215,183
	Denominator:
	Weighted-average common shares outstanding:
	Basic		35,991,402		41,398,251		35,961,002		38,810,473
	Diluted		35,991,402		43,196,754		35,961,002		40,861,295
	Net income (loss) per share:
	Basic	$	-0.23	$	0.54	$	-0.34	$	0.5
	Diluted	$	-0.23	$	0.52	$	-0.34	$	0.47
	Common stock equivalents
	As of June 30, 2013 and 2014, the following number of potential common stock equivalents were outstanding:
		As of June 30,
		2013		2014
	Outstanding common stock options		5,128,059		5,955,257
	Outstanding warrants		133,968		34,647
	Outstanding PRSUs		272,750		270,386
	Outstanding RSUs		—		191,464
	Shares to be purchased under the ESPP		—		2,092
	Total		5,534,777		6,453,846
	These common stock equivalents were excluded from the determination of diluted net loss per share for the three and six months ended June 30, 2013 due to their anti-dilutive effect on earnings.
	The following weighted-average outstanding common stock options, warrants, RSUs and shares to be purchased under the ESPP were added to basic weighted-average common shares outstanding for the three and six months ended June 30, 2014 to calculate diluted weighted-average shares outstanding because of their dilutive effect:
		Three		Six Months
		Months		Ended June
		Ended June		30,
		30,
		2013		2014
	Outstanding common stock options		1,771,695		2,008,581
	Outstanding warrants		9,728		12,822
	Outstanding RSUs		16,035		28,242
	Shares to be purchased under the ESPP		1,045		1,177
	Total		1,798,503		2,050,822

New_Accounting_Pronouncements

New Accounting Pronouncements	6 Months Ended
	Jun. 30, 2014
Accounting Changes and Error Corrections [Abstract]	'
Accounting Changes and Error Corrections [Text Block]	'
	3. New Accounting Pronouncements
	Recently Adopted Accounting Standards
	In May 2014, the FASB issued Accounting Standards Update ("ASU") 2014-09, Revenue from Contracts with Customers (Topic 606), to clarify the principles used to recognize revenue for all entities. Under the new standard, an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In order to do so, an entity would follow the five-step process for in-scope transactions: 1) identify the contract with a customer, 2) identify the separate performance obligations in the contract, 3) determine the transaction price, 4) allocate the transaction price to the separate performance obligations in the contract, and 5) recognize revenue when (or as) the entity satisfies a performance obligation. The provisions of the new standard are effective for the Company for annual reporting periods beginning after December 15, 2016 and early adoption is not permitted. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. The Company is currently evaluating the impact, if any, the adoption of this guidance will have on its consolidated financial statements.
	In July 2013, the FASB issued ASU No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists, an update to ASC Topic 740, Income Taxes. This amendment provides clarification regarding the presentation of an unrecognized tax benefit related to a net operating loss carryforward, a similar tax loss, or a tax credit carryforward. Under this new standard, the liability related to an unrecognized tax benefit, or a portion thereof, should be presented in the financial statements as a reduction to a deferred tax asset if available under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position. Otherwise, the unrecognized tax benefit should be presented in the financial statements as a separate liability. The assessment is based on the unrecognized tax benefit and deferred tax asset that exist at the reporting date. The provisions of the new standard were effective on a prospective basis beginning in 2014 for annual and interim reporting periods. This update became effective for the Company beginning January 1, 2014. The adoption did not have a material impact on the Company’s interim consolidated financial statements.

Other_Comprehensive_Income_Los

Other Comprehensive Income (Loss)	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity Note [Abstract]	'
Other Comprehensive Income (Loss) [Text Block]	'
	4. Other Comprehensive Income (Loss)
	The following tables summarize the accumulated balances related to each component of other comprehensive income (loss) for the three months ended June 30, 2013 and 2014:
		Foreign Currency		Unrealized Net		Accumulated Other
		Translation Losses		Gains (Losses)		Comprehensive
				on Securities		Income (Loss)
	Balance at March 31, 2013	$	-4,381	$	37,546	$	33,165
	Unrealized loss		-21,880		-98,412		-120,292
	Net amount reclassified to net income (loss)		—		-425		-425
	Other comprehensive loss		-21,880		-98,837		-120,717
	Balance at June 30, 2013	$	-26,261		-61,291		-87,552
				Unrealized Net		Accumulated Other
		Foreign Currency		Gains (Losses)		Comprehensive
		Translation Losses		on Securities		Income (Loss)
	Balance at March 31, 2014	$	-11,306	$	59,650	$	48,344
	Unrealized loss		-29,010		-57,521		-86,531
	Net amount reclassified to net income (loss)		—		—		—
	Other comprehensive loss		-29,010		-57,521		-86,531
	Balance at June 30, 2014	$	-40,316		2,129		-38,187
	The following tables summarize the accumulated balances related to each component of other comprehensive income (loss) for the six months ended June 30, 2013 and 2014:
				Unrealized Net		Accumulated Other
		Foreign Currency		Gains (Losses)		Comprehensive
		Translation Losses		on Securities		Income (Loss)
	Balance at December 31, 2012	$	-5,011	$	77,760	$	72,749
	Unrealized loss		-21,250		-134,671		-155,921
	Net amount reclassified to net income (loss)		—		-4,380		-4,380
	Other comprehensive loss		-21,250		-139,051		-160,301
	Balance at June 30, 2013	$	-26,261		-61,291		-87,552
				Unrealized Net		Accumulated Other
		Foreign Currency		Gains (Losses)		Comprehensive
		Translation Losses		on Securities		Income (Loss)
	Balance at December 31, 2013	$	-11,816	$	68,507	$	56,691
	Unrealized loss		-28,500		-66,378		-94,878
	Net amount reclassified to net income (loss)		—		—		—
	Other comprehensive loss		-28,500		-66,378		-94,878
	Balance at June 30, 2014	$	-40,316		2,129		-38,187
	The assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows, which results in translation adjustments being made in stockholders’ equity rather than to net income (loss).
	For the three and six months ended June 30, 2014, there were no amounts reclassified out of Accumulated Other Comprehensive Income.

Investments

Investments	6 Months Ended
	Jun. 30, 2014
Investments, Debt and Equity Securities [Abstract]	'
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	'
	5. Investments
	The Company applies the fair value measurement and disclosure provisions of ASC Topic 820, Fair Value Measurements and Disclosures (“ASC 820”). ASC 820, which defines fair value, establishes a framework for measuring fair value in GAAP, and expands disclosures about fair value measurements. Investments consist primarily of investments with original maturities greater than three months, but no longer than 24 months when purchased.
	ASC 820 establishes a three-level valuation hierarchy for fair value measurements. These valuation techniques are based upon the transparency of inputs (observable and unobservable) to the valuation of an asset or liability as of the measurement date. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs create the following fair value hierarchy:
	Level 1  — Valuation is based on quoted prices for identical assets or liabilities in active markets.
	Level 2  — Valuation is based on quoted prices for similar assets or liabilities in active markets, or other inputs that are observable for the asset or liability, either directly or indirectly, for the full term of the financial instrument.
	Level 3  — Valuation is based upon other unobservable inputs that are significant to the fair value measurement.
	The fair value of the Company’s fixed income securities is based on a market approach using quoted market values.
	The following table summarizes the fair value of cash and cash equivalents and investments as of December 31, 2013:
	Description	Cost		Level 1		Level 2		Fair Value
								(Carrying
								Value)
	Cash
	Cash	$	7,887,502	$	7,887,502	$	—	$	7,887,502
	Cash equivalents
	Money market funds		44,959,438		44,959,438		—		44,959,438
	Cash and cash equivalents	$	52,846,940	$	52,846,940	$	—	$	52,846,940
	Short-term investments (due within 1 year)
	U.S. government treasury obligations	$	5,009,194	$	5,013,850	$	—	$	5,013,850
	U.S. government agency obligations		33,598,370		33,609,886		—		33,609,886
	Corporate obligations		31,789,117		—		31,810,412		31,810,412
	Total short-term investments	$	70,396,681	$	38,623,736	$	31,810,412	$	70,434,148
	Long-term investments (due after 1 year through 2 years)
	U.S. government agency obligations	$	14,807,642	$	14,821,065	$	—	$	14,821,065
	Corporate obligations		10,743,707		—		10,750,594		10,750,594
	Total long-term investments	$	25,551,349	$	14,821,065	$	10,750,594	$	25,571,659
	The following table summarizes the fair value of cash and cash equivalents and investments as of June 30, 2014:
	Description	Cost		Level 1		Level 2		Fair Value
								(Carrying
								Value)
	Cash
	Cash	$	10,765,408	$	10,765,408	$	—	$	10,765,408
	Cash equivalents
	Money market funds		20,803,095		20,803,095		—		20,803,095
	Cash and cash equivalents	$	31,568,503	$	31,568,503	$	—	$	31,568,503
	Short-term investments (due within 1 year)
	U.S. government treasury obligations	$	5,000,246	$	5,000,800	$	—	$	5,000,800
	U.S. government agency obligations		48,680,354		48,704,565		—		48,704,565
	Corporate obligations		35,827,332		—		35,828,375		35,828,375
	Total short-term investments	$	89,507,932	$	53,705,365	$	35,828,375	$	89,533,740
	Long-term investments (due after 1 year through 2 years)
	U.S. government treasury obligations	$	25,650,619	$	25,672,825	$	—	$	25,672,825
	U.S. government agency obligations		43,048,665		43,012,895		—		43,012,895
	Corporate obligations		29,422,008		—		29,411,893		29,411,893
	Total long-term investments	$	98,121,292	$	68,685,720	$	29,411,893	$	98,097,613
	All securities held at December 31, 2013 and June 30, 2014, were classified as available-for-sale as defined by ASC 320.
	Total unrealized gross gains were $20,410 and $80,174 as of June 30, 2013 and 2014, respectively. Total unrealized gross losses were $81,701 and $78,045 as of June 30, 2013 and 2014, respectively. The Company does not consider any of the unrealized losses to be other-than-temporary impairments because the Company has the intent and ability to hold investments until they recover in value.

Collaborations

Collaborations	6 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Collaborative Arrangement Disclosure [Text Block]	'
	6. Collaborations
	Merck Collaboration Agreement
	In April 2012, the Company entered into a worldwide collaboration agreement with Merck Sharp & Dohme Research GmbH, a subsidiary of Merck & Co, Inc. (“Merck”), regarding the development and commercialization of vintafolide, which agreement has been terminated by Merck effective September 15, 2014. As a result of the termination of the collaboration with Merck, the Company is no longer eligible for additional milestone payments from Merck. In addition, all obligations of the Company under the agreement have been fulfilled and the Company is not required to perform any additional services to Merck. Pursuant to the collaboration agreement, the Company received a $120.0 million non-refundable upfront payment and a $5.0 million milestone payment in 2012. Under the collaboration agreement, the Company is responsible for the majority of funding and completion of the Phase 3 PROCEED clinical trial of vintafolide for the treatment of patients with platinum-resistant ovarian cancer (“PROC”), which was terminated in May 2014. The Company is responsible for the execution of the Phase 2b TARGET trial of vintafolide for the treatment of second line non-small cell lung cancer, which is now substantially complete, pending the receipt of final overall survival results. Merck is responsible for the costs of the TARGET trial through September 15, 2014.
	For revenue recognition purposes, the Company viewed the collaboration with Merck as a multiple element arrangement. Multiple element arrangements are analyzed to determine whether the various performance obligations, or elements, can be separated or whether they must be accounted for as a single unit of accounting. The Company evaluated whether the delivered elements under the arrangement have value on a stand-alone basis and whether objective and reliable evidence of fair value of the undelivered element exists. Deliverables that do not meet these criteria are not evaluated separately for the purpose of revenue recognition. For a single unit of accounting, payments received are recognized in a manner consistent with the final deliverable. The Company determined that the deliverables related to the collaboration with Merck, including the licenses granted to Merck, as well as the Company performance obligations to provide various research and development services, would be accounted for as a single unit of account. This determination was made because the successful development of the therapeutic drug, vintafolide, is dependent on the companion diagnostic, etarfolatide, to select patients who are most likely to receive the most benefit from vintafolide. Given the nature of the combined benefit of the companion diagnostic and the therapeutic drug, the research and development services to be provided by the Company were essential to the overall arrangement as the Company has significant knowledge and technical know-how that was important to realizing the value of the licenses granted. Subsequent to the inception of the Merck arrangement, the Company evaluated the remaining deliverables for separation as items in the arrangement were delivered.
	The Company has been recognizing the non-refundable $120.0 million upfront payment, the $5.0 million milestone payment and funding from the research and development services on a straight-line basis over the performance period, which started at the date of execution of the agreement. Based on the termination of the PROCEED trial in May 2014 and receiving the notice of termination of the collaboration agreement in June 2014, the Company concluded that all of its obligations under the agreement have been fulfilled and the Company is not required to perform any additional services to Merck, and as a result the balance of deferred revenue related to the collaboration agreement of $31.1 million was recognized in June 2014. The Company recognized approximately $49.2 million and $66.4 million of collaboration revenue during the three and six months ended June 30, 2014, respectively. Though accounted for as a single unit of account for presentation purposes, the Company made an allocation of revenue recognized as collaboration revenue between the license and the services. This allocation was based upon the relative selling price of each deliverable. For the three and six months ended June 30, 2014, license revenue was approximately $39.0 million and $52.7 million, respectively, while research and development services were approximately $10.2 million and $13.7 million, respectively, of the collaboration revenue.
	In July 2014, Merck and the Company entered into a letter agreement whereby Merck agreed to pay (i) $2.2 million of expenses related to costs incurred to prepare for the increase in the number of FR(100%) patients (patients in which 100 percent of their target lesions over-expressed the folate receptor as determined by an etarfolatide scan) in the PROCEED trial from 250 to 350, for which Merck agreed to reimburse at 75%, and (ii) its portion of the remaining PROCEED trial expenses beyond the September 15, 2014 termination date. The Company has no obligations nor is it required to perform any additional services under the letter agreement. Revenue for these additional payments will be recognized in future periods.
	NMP License and Commercialization Agreement
	In August 2013, the Company entered into a license and commercialization agreement with Nihon Medi-Physic Co., LTD. (“NMP”) that grants NMP the right to develop and commercialize etarfolatide in Japan for use in connection with vintafolide in Japan. The Company received a $1.0 million non-refundable upfront payment, is eligible for up to $4.5 million based on the successful achievement of regulatory goals for etarfolatide in five different cancer indications and is eligible to receive double-digit percentage royalties on sales of etarfolatide in Japan.
	For revenue recognition purposes, the Company viewed the agreement with NMP as a multiple element arrangement. Multiple element arrangements are analyzed to determine whether the various performance obligations, or elements, can be separated or whether they must be accounted for as a single unit of accounting. The Company has identified the deliverables related to the collaboration with NMP, which include the license granted to NMP, as well as the obligation to provide preclinical and clinical supply of etarfolatide, to provide rights to NMP if a product is developed that replaces etarfolatide, obligation for the Company to provide clinical data to NMP during the contract period and coordination of development and commercialization efforts between the Company for vintafolide and NMP for etarfolatide in Japan. The Company’s deliverables will be accounted for as a single unit of account, therefore the non-refundable upfront payment will be recognized on a straight-line basis over the performance period. This determination was made because the successful development of etarfolatide in Japan requires the ongoing participation by the Company, including the development of the related therapeutic drug, vintafolide. The performance period over which the revenue will be recognized continues from the date of execution of the agreement through the end of 2033, the estimated termination date of the contract which is when the Company’s performance obligations will be completed. Any significant changes in the timing of the performance period could result in a change in the revenue recognition period. The Company had deferred revenue related to the agreement of approximately $1.0 million at June 30, 2014. Subsequent to the inception of the NMP arrangement, the Company evaluates the remaining deliverables for separation as items in the arrangement are delivered.
	The arrangement with NMP includes milestone payments of up to approximately $4.5 million and the milestones are based on the commencement of clinical trials in Japan for specific and non-specific indications and filing for approval in Japan for specific and non-specific indications. The Company evaluated each of these milestone payments and believes that all of the milestones are substantive as there is substantial performance risk that must occur in order for them to be met because the Company must complete additional clinical trials which show a positive outcome or receive approval from a regulatory authority and would be commensurate with the enhancement of value of the underlying intellectual property. To date, the products have not been approved in Japan and no revenue has been recognized related to the regulatory milestones or royalties.
	NMP has the right to terminate the collaboration agreement on 90 days notice prior to first commercial sale in Japan and six months notice after the first commercial sale in Japan. NMP also has the right to terminate the agreement on six months notice if the Company fails to launch vintafolide after receiving regulatory approval in Japan. NMP and the Company each have the right to terminate the agreement due to the material breach or insolvency of the other party. Upon termination of the agreement depending on the circumstances, the parties have varying rights and obligations with respect to licensing and related regulatory materials and data.

Stockholders_Equity_Deficit

Stockholders' Equity (Deficit)	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	7. Stockholders’ Equity (Deficit)
	Public Offering
	On April 2 2014, the Company completed a public offering of 5,175,000 shares of its common stock in a public offering. Proceeds, net of underwriting discounts, commissions and other transaction costs, were $101.9 million.
	Stock-Based Compensation Plans
	The Company has had stock-based compensation plans since 1997. The awards made under the plans adopted in 1997 and 2007 consisted of stock options. The 2010 Equity Incentive Plan (the “2010 Plan”), which is the only plan under which awards may currently be made, authorizes awards in the form of stock options, stock appreciation rights, restricted stock, PRSUs, performance units and performance shares, and RSUs. Awards under the 2010 Plan may be made to employees, directors and certain consultants as determined by the compensation committee of the board of directors. There were 6,625,563 and 8,071,563 shares of common stock authorized and reserved at December 31, 2013 and June 30, 2014 under these plans, respectively.
	Stock Options
	Under the various plans, employees have been granted incentive stock options, while directors and consultants have been granted non-qualified options. The plans allow the holder of an option to purchase common stock at the exercise price, which was at or above the fair value of the Company’s common stock on the date of grant.
	Generally, options granted under the 1997 and 2007 plans in connection with an employee’s commencement of employment vest over a four-year period with one-half of the shares subject to the grant vesting after two years of employment and remaining options vesting monthly over the remainder of the four-year period. Options granted under the 1997 and 2007 plans for performance or promotions vest monthly over a four-year period. Generally, options granted under the 2010 Plan vest annually over a four-year period. Unexercised stock options terminate on the tenth anniversary date after the date of grant. The Company recognizes stock-based compensation expense over the requisite service period of the individual grantees, which generally equals the vesting period. The Company utilizes a Black-Scholes option-pricing model to estimate the value of stock options. The Black-Scholes model allows the use of a range of assumptions related to volatility, risk-free interest rate, employee exercise behavior and dividend yield. Prior to 2013, since the Company did not have sufficient history as a publicly traded company to evaluate volatility, the Company used an average of several peer companies’ volatilities to determine a reasonable estimate of volatility. Beginning in 2013, the Company utilizes a combination of peer volatility and company volatility. For purposes of identifying peer companies, the Company considered characteristics such as industry, length of trading history, market capitalization and similar product pipelines.
	Due to insufficient history as a public company, the Company is using the “simplified” method for “plain vanilla” options to estimate the expected term of the stock options grants. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option. The risk-free interest rate assumption is derived from the weighted-average yield of a Treasury security with the same term as the expected life of the options, and the dividend yield assumption is based on historical experience and the Company’s estimate of future dividend yields.
	The weighted-average value of the individual options granted during the three and six months ended June 30, 2013 and 2014 were determined using the following assumptions:
		Three Months				Six Months
		Ended				Ended
		June 30,				June 30,
		2013		2014		2013		2014
	Weighted-average volatility	102	%	107	%	101.2	%	102.8	%
	Risk-free interest rate	1.78	%	2.34	%	1.19	%	1.98	%
	Weighted-average expected life (in years)	7.9		8.9		6.6		6.7
	Dividend yield	0	%	0	%	0	%	0	%
	The Company’s stock option activity and related information are summarized as follows:
		Options		Weighted-			Weighted-		Aggregate
				Average			Average		Intrinsic
				Exercise			Remaining		Value
				Price			Contractual
							Term
							(In Years)
	Outstanding at January 1, 2014	5,246,465		$	6.76
	Granted during period	856,261			11.13
	Exercised during period	-147,091			3.27
	Expired during period	—			—
	Forfeited during period	-15,925			16.42
	Outstanding at March 31, 2014	5,939,710		$	7.45		7.6		$	97,181,600
	Exercisable at March 31, 2014	2,697,802		$	5.1		6.2		$	50,465,826
	Outstanding at April 1, 2014	5,939,710
	Granted during period	155,975		$	8.81
	Exercised during period	-39,709		$	2.51
	Expired during period	-255		$	6.69
	Forfeited during period	-100,464		$	15.08
	Outstanding at June 30, 2014	5,955,257		$	7.39		7.4		$	7,864,108
	Exercisable at June 30, 2014	2,985,828		$	5.76		6.2		$	6,175,294
	As of June 30, 2014, the total remaining unrecognized compensation cost related to stock options was $18.4 million, which is being amortized over the remaining requisite service period. The expense is expected to be recognized over a weighted average period of 1.8 years.
	Restricted Stock Units
	In May 2011, the Company adopted and granted awards under a performance-based RSU program (the “2011 PRSU Program”) under the 2010 Plan. Each unit represents an amount equal to one share of the Company’s common stock. The PRSUs will be earned, in whole or in part, based on performance and service conditions. The performance condition is based upon whether the Company receives regulatory approval to sell a therapeutic product, and the awards include a target number of PRSUs that will vest upon a First Commercial Approval, and a maximum number of PRSUs that will vest upon a Second Commercial Approval. Any earned PRSUs will vest fifty percent based on the performance condition of commercial approval and fifty percent one year thereafter to fulfill the service condition, which requires the employee to remain employed by the Company.
	As of June 30, 2014, the Company had 270,386 PRSU awards outstanding. The unrecorded stock compensation expense is based on number of units granted, less estimated forfeitures based on the Company’s historical forfeiture rate of 6.49%, and the closing market price of the Company’s common stock at the grant date. As of June 30, 2014, the performance condition of obtaining regulatory approval had not been achieved, therefore, no vesting had occurred. The awards are being accounted for under ASC 718, and compensation expense is to be recorded if the Company determines that it is probable that the performance conditions will be achieved. As of June 30, 2014, it was not probable that the performance conditions will be achieved, therefore, no compensation expense related to the PRSUs was recorded for the three and six months ended June 30, 2014. Unrecorded compensation expense for the 2011 PRSU Program as of June 30, 2014 was $2.7 million.
	As of June 30, 2014, the Company had 191,464 RSU awards outstanding under the 2010 Plan which were granted in February 2014. The RSUs are service-based awards that will vest and be paid in four equal installments annually beginning in February 2015 in the form of one share of the Company’s common stock for each RSU. The awards were granted at a weighted average fair value of $11.11 per share. As of June 30, 2014, the total remaining unrecognized compensation cost related to RSUs was $1.9 million, which is being amortized over the remaining requisite service period, and had a weighted average remaining life of 2.3 years.
	Employee Stock Purchase Plan
	Effective January 1, 2014, the Company implemented the ESPP. At January 1, 2014, 622,780 common shares were available for issuance under the ESPP. Shares may be issued under the ESPP twice a year. In the three and six months ended June 30, 2014, plan participants purchased 32,168 shares of common stock under the ESPP at an average purchase price of $5.94 per share. At June 30, 2014, 590,612 shares were available for issuance under the ESPP.

Income_Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	8. Income Taxes
	The Company accounts for income taxes under the liability method in accordance with the provisions of ASC Topic 740, Income Taxes. The Company recognizes future tax benefits, such as net operating losses, to the extent those benefits are expected to be realized in future periods. Due to uncertainty surrounding the realization of its deferred tax assets, the Company has recorded a valuation allowance against its net deferred tax assets. The Company experienced a change in ownership as defined under Section 382 of the U.S. Internal Revenue Code in August 2011. As a result, the future use of its net operating losses and credit equivalents is currently limited to approximately $ 133.2 million for 2014, $39.0 million for 2015, $29.7 million for 2016 and $16.8 million for 2017. Any available but unused amounts will become available for use in all successive years.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	9. Commitments and Contingencies
	On June 24, 2014, a complaint in a securities class action lawsuit was filed against the Company and one of its officers and directors in the United States District Court for the Southern District of Indiana under the following caption: Tony Nguyen, on Behalf of Himself and All Others Similarly Situated v. Endocyte, Inc. and P. Ron Ellis. The complaint alleges, among other things, that the defendants made false and misleading statements about the efficacy of vintafolide, and violated Section 10(b) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and Rule 10b-5 promulgated thereunder, by, among other things: employing devices, schemes and artifices to defraud; making untrue statements of material facts or omitting to state material facts necessary in order to make the statements made, in light of the circumstances under which they were made, not misleading; or engaging in acts, practices and a course of business that operated as a fraud or deceit upon plaintiff and others similarly situated in connection with their purchases of the Company’s securities during the class period. The complaint also alleges that Mr. Ellis violated Section 20(a) of the Exchange Act, as a control person, by causing the Company to engage in the wrongful conduct alleged in the complaint. The complaint alleges that the alleged violations resulted in plaintiff purchasing the Company’s securities at artificially inflated prices. The putative class period in this action is from March 21, 2014 through May 2, 2014. The plaintiff seeks the designation of this action as a class action, an award of unspecified damages, interest, costs, expert fees and attorneys’ fees, and such equitable/injunctive or other relief as the court may deem just and proper. The Company believes that this lawsuit is without merit and intends to defend itself vigorously against the allegations made in the complaint.
	On July 13, 2014, a complaint in a securities class action lawsuit was filed against the Company and one of its officers and directors in the United States District Court for the Southern District of Indiana under the following caption: Vivian Oh Revocable Trust, Individually and on Behalf of All Others Similarly Situated v. Endocyte, Inc. and P. Ron Ellis. The complaint alleges, among other things, that the defendants made false and misleading statements about vintafolide’s Phase 3 trial and its future prospects, and violated Section 10(b) of the Exchange Act and Rule 10b-5 promulgated thereunder, by, among other things: employing devices, schemes and artifices to defraud; making untrue statements of material fact or omitting to state material facts necessary in order to make the statements made not misleading; or engaging in acts, practices and a course of business which operated as a fraud and deceit upon purchasers of the Company’s securities during the class period. The complaint also alleges that Mr. Ellis violated Section 20(a) of the Exchange Act, as a control person, by, among other things, influencing and controlling the Company’s decision-making, including the content and dissemination of the various statements with plaintiff contends are false and misleading, causing the Company to engage in the wrongful conduct alleged in the complaint. The complaint alleges that the alleged violations resulted in plaintiff purchasing the Company’s securities at artificially inflated prices. The putative class period in this action is from March 21, 2014 through May 2, 2014. The plaintiff seeks the designation of this action as a class action, an award of unspecified compensatory damages, interest, costs, expenses, including counsel fees and expert fees, and such other relief as the court may deem just and proper. The Company believes that this lawsuit is without merit and intends to defend itself vigorously against the allegations made in the complaint.

Restructuring_Costs

Restructuring Costs	6 Months Ended
	Jun. 30, 2014
Restructuring Costs [Abstract]	'
Restructuring and Related Activities Disclosure [Text Block]	'
	10. Restructuring Costs
	The Company terminated the PROCEED trial in May 2014 after the interim futility analysis indicated that vintafolide did not demonstrate efficacy on the pre-specified outcome of progression-free survival  for the treatment of PROC. As a result, the Company ceased its pre-launch commercial activities in Europe and implemented staff reductions in Europe and in the U.S. Included in general and administrative expenses for the three and six months ended June 30, 2014, were expenses for employee termination benefits and contract termination costs of $1.3 million, and included in research and development expenses were  $4.8 million of expenses for the PROCEED trial, including site close-out expenses. As of June 30, 2014, the Company had a clinical trial accrual balance related to the PROCEED trial termination of $4.8 million, a severance accrual balance of $0.7 million and a contract termination accrual balance of $0.4 million, which are expected to be fully paid by June 2015.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	Basis of Presentation
	The accompanying condensed consolidated financial statements include the accounts of Endocyte, Inc. and its subsidiaries and all intercompany amounts have been eliminated. The condensed consolidated financial statements are prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) for interim financial information to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring accruals and revisions of estimates, considered necessary for a fair presentation of the accompanying condensed consolidated financial statements have been included. Interim results for the three and six  months ended June 30, 2014 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2014 or any other future period. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013. Subsequent events have been evaluated through the date of issuance, which is the same as the date this Form 10-Q is filed with the Securities and Exchange Commission.
Segment Reporting, Policy [Policy Text Block]	'
	Segment Information
	Operating segments are defined as components of an enterprise engaging in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company performs clinical trials globally and has established a subsidiary in The Netherlands to assist in the administration of filing applications in Europe and a subsidiary in Switzerland for commercial pre-launch activities in Europe. The applications filed in Europe were withdrawn in May 2014 and the pre-launch activities in Europe ceased. All long-lived assets are held in the U.S. The Company views its operations and manages its business in one operating segment.
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual amounts could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash and Cash Equivalents
	The Company considers cash and all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents consist primarily of money market instruments that are maintained by an investment manager.
Investment, Policy [Policy Text Block]	'
	Investments
	Investments consist primarily of investments in U.S. Treasuries, U.S. Government agency obligations and corporate debt securities, which could also include commercial paper, that are maintained by an investment manager. Management determines the appropriate classification of marketable securities at the time of purchase and reevaluates such classification as of each balance sheet date. Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in other comprehensive income. Realized gains and losses and declines in value judged to be other-than-temporary on available-for-sale securities are included in other income. The Company considers and accounts for other-than-temporary impairments according to the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 320, Investments — Debt and Equity Securities (“ASC 320”). The cost of securities sold is based on the specific-identification method. Discounts and premiums on debt securities are amortized to interest income and expense over the term of the security.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition
	The Company recognizes revenues from license and collaboration agreements when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the fee is fixed or determinable, and there is reasonable assurance that the related amounts are collectible in accordance with ASC Topic 605, Revenue Recognition (“ASC 605”). The Company’s license and collaboration agreements may contain multiple elements, including grants of licenses to intellectual property rights, agreement to provide research and development services and other deliverables. The deliverables under such arrangements are evaluated under ASC Subtopic 605-25, Multiple-Element Arrangements. Under ASC 605-25, each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting based on whether the deliverable has “stand-alone value” to the customer. The arrangement’s consideration that is fixed or determinable, excluding contingent milestone payments, is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. In general, the consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables.
	Upfront payments for licensing the Company's intellectual property are evaluated to determine if the licensee can obtain stand-alone value from the license separate from the value of the research and development services and other deliverables in the arrangement to be provided by the Company. If at the inception of an arrangement the Company determines that the license does not have stand-alone value separate from the research and development services or other deliverables, the license, services and other deliverables are combined as one unit of account and upfront payments are recorded as deferred revenue in the balance sheet and are recognized in a manner consistent with the final deliverable. Subsequent to the inception of an arrangement, the Company evaluates the remaining deliverables for separation as items in the arrangement are delivered. When stand-alone value is identified, the related consideration is recorded as revenue in the period in which the license or other intellectual property rights are delivered.
	In those circumstances where research and development services or other deliverables are combined with the license, and multiple services are being performed such that a common output measure to determine a pattern of performance cannot be discerned, the Company recognizes amounts received on a straight line basis over the performance period. Such amounts are recorded as collaboration revenue. Any subsequent reimbursement payments, which are contingent upon the Company’s future research and development expenditures, will be recorded as collaboration revenue and will be recognized on a straight-line basis over the performance period using the cumulative catch up method. The costs associated with these activities are reflected as a component of research and development expense in the statements of operations in the period incurred. In the event of an early termination of a collaboration agreement, any deferred revenue is recognized in the period in which all obligations of the Company under the agreement have been fulfilled.
	Milestone payments under collaborative arrangements are triggered either by the results of the Company’s research and development efforts, achievement of regulatory goals or by specified sales results by a third-party collaborator. Milestones related to the Company’s development-based activities may include initiation of various phases of clinical trials and applications and acceptance for product approvals by regulatory agencies. Due to the uncertainty involved in meeting these development-based milestones, the determination is made at the inception of the collaboration agreement whether the development-based milestones are considered to be substantive (i.e. not just achieved through passage of time). In addition, the amounts of the payments assigned thereto are considered to be commensurate with the enhancement of the value of the delivered intellectual property as a result of the Company’s performance. Because the Company’s involvement is necessary to the achievement of development-based milestones, the Company would account for development-based milestones as revenue upon achievement of the substantive milestone events. Milestones related to sales-based activities may be triggered upon events such as first commercial sale of a product or when sales first achieve a defined level. Since these sales-based milestones would be achieved after the completion of the Company’s development activities, the Company would account for the sales-based milestones in the same manner as royalties, with revenue recognized upon achievement of the milestone.
	Royalties based on reported sales of licensed products will be recognized based on contract terms when reported sales are reliably measurable and collectability is reasonably assured. To date, none of the Company's products have been approved and therefore the Company has not earned any royalty revenue from product sales. In territories where the Company and the collaborator will share profit, the revenue will be recorded in the period earned.
Research and Development Expense, Policy [Policy Text Block]	'
	Research and Development Expenses
	Research and development expenses represent costs associated with the ongoing development of SMDCs and companion imaging agents and include salaries, supplies, and expenses for clinical trials. The Company records accruals for clinical trial expenses based on the estimated amount of work completed. The Company monitors patient enrollment levels and related activities to the extent possible through internal reviews, correspondence, and discussions with research organizations. In the event that a clinical trial is terminated early, the Company records, in the period of termination, an accrual for the estimated remaining costs to complete the trial.
	Upfront payments made in connection with business collaborations and research and development arrangements are evaluated under ASC Subtopic 730-20, Research and Development Arrangements. Upfront payments made in connection with business development collaborations are expensed as research and development costs, as the assets acquired do not have alternative future use. Amounts related to future research and development are capitalized as prepaid research and development and are expensed over the service period based upon the level of services provided. As of June 30, 2014, the Company had approximately $0.6 million of capitalized research and development costs included in prepaid expenses and other noncurrent assets.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-Based Compensation
	The Company accounts for its stock options pursuant to ASC Topic 718, Compensation — Stock Compensation (“ASC 718”), which requires the recognition of the fair value, or calculated value for nonpublic entities, of stock-based compensation in net income. Stock-based compensation consists of stock options, which are granted at exercise prices at or above the fair market value of the Company’s common stock on the dates of grant. The Company has issued performance-based restricted stock units (“PRSUs”) for which stock-based compensation expense will be recognized when the Company determines that it is probable that the performance conditions will be achieved. The Company has also issued service-based restricted stock units (“RSUs”) for which stock-based compensation expense is recognized ratably over the service period. The Company used the calculated value method to measure its stock-based compensation prior to its initial public offering. The Company recognizes compensation cost based on the grant-date value estimated in accordance with the provisions of ASC 718.
Earnings Per Share, Policy [Policy Text Block]	'
	Net Income (Loss) Per Share
	Basic net income (loss) per share is calculated by dividing the net income (loss) attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. For purposes of this calculation, stock options, warrants, PRSUs, RSUs and shares to be purchased under the Company’s 2010 Employee Stock Purchase Plan (“ESPP”) are considered to be common stock equivalents and are only included in the calculation of diluted net income (loss) per share when their effect is dilutive.
	The following tables and discussion provide a reconciliation of the numerator and denominator of the basic and diluted net income (loss) per share computations. The calculation below provides net income (loss), weighted-average common shares outstanding, and the resultant net income (loss) per share on both a basic and diluted basis for the three and six months ended June 30, 2013 and 2014.
	Historical net income (loss) per share
		Three Months Ended June 30,				Six Months Ended June 30,
		2013		2014		2013		2014
	Numerator:
	Net income (loss)	$	-8,227,476	$	22,356,642	$	-12,089,147	$	19,215,183
	Denominator:
	Weighted-average common shares outstanding:
	Basic		35,991,402		41,398,251		35,961,002		38,810,473
	Diluted		35,991,402		43,196,754		35,961,002		40,861,295
	Net income (loss) per share:
	Basic	$	-0.23	$	0.54	$	-0.34	$	0.5
	Diluted	$	-0.23	$	0.52	$	-0.34	$	0.47
	Common stock equivalents
	As of June 30, 2013 and 2014, the following number of potential common stock equivalents were outstanding:
		As of June 30,
		2013		2014
	Outstanding common stock options		5,128,059		5,955,257
	Outstanding warrants		133,968		34,647
	Outstanding PRSUs		272,750		270,386
	Outstanding RSUs		—		191,464
	Shares to be purchased under the ESPP		—		2,092
	Total		5,534,777		6,453,846
	These common stock equivalents were excluded from the determination of diluted net loss per share for the three and six months ended June 30, 2013 due to their anti-dilutive effect on earnings.
	The following weighted-average outstanding common stock options, warrants, RSUs and shares to be purchased under the ESPP were added to basic weighted-average common shares outstanding for the three and six months ended June 30, 2014 to calculate diluted weighted-average shares outstanding because of their dilutive effect:
		Three		Six Months
		Months		Ended June
		Ended June		30,
		30,
		2013		2014
	Outstanding common stock options		1,771,695		2,008,581
	Outstanding warrants		9,728		12,822
	Outstanding RSUs		16,035		28,242
	Shares to be purchased under the ESPP		1,045		1,177
	Total		1,798,503		2,050,822

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
	The following tables and discussion provide a reconciliation of the numerator and denominator of the basic and diluted net income (loss) per share computations. The calculation below provides net income (loss), weighted-average common shares outstanding, and the resultant net income (loss) per share on both a basic and diluted basis for the three and six months ended June 30, 2013 and 2014.
	Historical net income (loss) per share
		Three Months Ended June 30,				Six Months Ended June 30,
		2013		2014		2013		2014
	Numerator:
	Net income (loss)	$	-8,227,476	$	22,356,642	$	-12,089,147	$	19,215,183
	Denominator:
	Weighted-average common shares outstanding:
	Basic		35,991,402		41,398,251		35,961,002		38,810,473
	Diluted		35,991,402		43,196,754		35,961,002		40,861,295
	Net income (loss) per share:
	Basic	$	-0.23	$	0.54	$	-0.34	$	0.5
	Diluted	$	-0.23	$	0.52	$	-0.34	$	0.47
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
	As of June 30, 2013 and 2014, the following number of potential common stock equivalents were outstanding:
		As of June 30,
		2013		2014
	Outstanding common stock options		5,128,059		5,955,257
	Outstanding warrants		133,968		34,647
	Outstanding PRSUs		272,750		270,386
	Outstanding RSUs		—		191,464
	Shares to be purchased under the ESPP		—		2,092
	Total		5,534,777		6,453,846
Schedule of Weighted Average Number of Shares [Table Text Block]	'
	The following weighted-average outstanding common stock options, warrants, RSUs and shares to be purchased under the ESPP were added to basic weighted-average common shares outstanding for the three and six months ended June 30, 2014 to calculate diluted weighted-average shares outstanding because of their dilutive effect:
		Three		Six Months
		Months		Ended June
		Ended June		30,
		30,
		2013		2014
	Outstanding common stock options		1,771,695		2,008,581
	Outstanding warrants		9,728		12,822
	Outstanding RSUs		16,035		28,242
	Shares to be purchased under the ESPP		1,045		1,177
	Total		1,798,503		2,050,822

Other_Comprehensive_Income_Los1

Other Comprehensive Income (Loss) (Tables)	6 Months Ended
	Jun. 30, 2014
Other Comprehensive Income (Loss), Tax [Abstract]	'
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	'
	The following tables summarize the accumulated balances related to each component of other comprehensive income (loss) for the three months ended June 30, 2013 and 2014:
		Foreign Currency		Unrealized Net		Accumulated Other
		Translation Losses		Gains (Losses)		Comprehensive
				on Securities		Income (Loss)
	Balance at March 31, 2013	$	-4,381	$	37,546	$	33,165
	Unrealized loss		-21,880		-98,412		-120,292
	Net amount reclassified to net income (loss)		—		-425		-425
	Other comprehensive loss		-21,880		-98,837		-120,717
	Balance at June 30, 2013	$	-26,261		-61,291		-87,552
				Unrealized Net		Accumulated Other
		Foreign Currency		Gains (Losses)		Comprehensive
		Translation Losses		on Securities		Income (Loss)
	Balance at March 31, 2014	$	-11,306	$	59,650	$	48,344
	Unrealized loss		-29,010		-57,521		-86,531
	Net amount reclassified to net income (loss)		—		—		—
	Other comprehensive loss		-29,010		-57,521		-86,531
	Balance at June 30, 2014	$	-40,316		2,129		-38,187
	The following tables summarize the accumulated balances related to each component of other comprehensive income (loss) for the six months ended June 30, 2013 and 2014:
				Unrealized Net		Accumulated Other
		Foreign Currency		Gains (Losses)		Comprehensive
		Translation Losses		on Securities		Income (Loss)
	Balance at December 31, 2012	$	-5,011	$	77,760	$	72,749
	Unrealized loss		-21,250		-134,671		-155,921
	Net amount reclassified to net income (loss)		—		-4,380		-4,380
	Other comprehensive loss		-21,250		-139,051		-160,301
	Balance at June 30, 2013	$	-26,261		-61,291		-87,552
				Unrealized Net		Accumulated Other
		Foreign Currency		Gains (Losses)		Comprehensive
		Translation Losses		on Securities		Income (Loss)
	Balance at December 31, 2013	$	-11,816	$	68,507	$	56,691
	Unrealized loss		-28,500		-66,378		-94,878
	Net amount reclassified to net income (loss)		—		—		—
	Other comprehensive loss		-28,500		-66,378		-94,878
	Balance at June 30, 2014	$	-40,316		2,129		-38,187

Investments_Tables

Investments (Tables)	6 Months Ended
	Jun. 30, 2014
Investments, Debt and Equity Securities [Abstract]	'
Schedule of Cash, Cash Equivalents and Short-term Investments [Table Text Block]	'
	The following table summarizes the fair value of cash and cash equivalents and investments as of December 31, 2013:
	Description	Cost		Level 1		Level 2		Fair Value
								(Carrying
								Value)
	Cash
	Cash	$	7,887,502	$	7,887,502	$	—	$	7,887,502
	Cash equivalents
	Money market funds		44,959,438		44,959,438		—		44,959,438
	Cash and cash equivalents	$	52,846,940	$	52,846,940	$	—	$	52,846,940
	Short-term investments (due within 1 year)
	U.S. government treasury obligations	$	5,009,194	$	5,013,850	$	—	$	5,013,850
	U.S. government agency obligations		33,598,370		33,609,886		—		33,609,886
	Corporate obligations		31,789,117		—		31,810,412		31,810,412
	Total short-term investments	$	70,396,681	$	38,623,736	$	31,810,412	$	70,434,148
	Long-term investments (due after 1 year through 2 years)
	U.S. government agency obligations	$	14,807,642	$	14,821,065	$	—	$	14,821,065
	Corporate obligations		10,743,707		—		10,750,594		10,750,594
	Total long-term investments	$	25,551,349	$	14,821,065	$	10,750,594	$	25,571,659
	The following table summarizes the fair value of cash and cash equivalents and investments as of June 30, 2014:
	Description	Cost		Level 1		Level 2		Fair Value
								(Carrying
								Value)
	Cash
	Cash	$	10,765,408	$	10,765,408	$	—	$	10,765,408
	Cash equivalents
	Money market funds		20,803,095		20,803,095		—		20,803,095
	Cash and cash equivalents	$	31,568,503	$	31,568,503	$	—	$	31,568,503
	Short-term investments (due within 1 year)
	U.S. government treasury obligations	$	5,000,246	$	5,000,800	$	—	$	5,000,800
	U.S. government agency obligations		48,680,354		48,704,565		—		48,704,565
	Corporate obligations		35,827,332		—		35,828,375		35,828,375
	Total short-term investments	$	89,507,932	$	53,705,365	$	35,828,375	$	89,533,740
	Long-term investments (due after 1 year through 2 years)
	U.S. government treasury obligations	$	25,650,619	$	25,672,825	$	—	$	25,672,825
	U.S. government agency obligations		43,048,665		43,012,895		—		43,012,895
	Corporate obligations		29,422,008		—		29,411,893		29,411,893
	Total long-term investments	$	98,121,292	$	68,685,720	$	29,411,893	$	98,097,613

Stockholders_Equity_Deficit_Ta

Stockholders' Equity (Deficit) (Tables)	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
	The weighted-average value of the individual options granted during the three and six months ended June 30, 2013 and 2014 were determined using the following assumptions:
		Three Months				Six Months
		Ended				Ended
		June 30,				June 30,
		2013		2014		2013		2014
	Weighted-average volatility	102	%	107	%	101.2	%	102.8	%
	Risk-free interest rate	1.78	%	2.34	%	1.19	%	1.98	%
	Weighted-average expected life (in years)	7.9		8.9		6.6		6.7
	Dividend yield	0	%	0	%	0	%	0	%
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The Company’s stock option activity and related information are summarized as follows:
		Options		Weighted-			Weighted-		Aggregate
				Average			Average		Intrinsic
				Exercise			Remaining		Value
				Price			Contractual
							Term
							(In Years)
	Outstanding at January 1, 2014	5,246,465		$	6.76
	Granted during period	856,261			11.13
	Exercised during period	-147,091			3.27
	Expired during period	—			—
	Forfeited during period	-15,925			16.42
	Outstanding at March 31, 2014	5,939,710		$	7.45		7.6		$	97,181,600
	Exercisable at March 31, 2014	2,697,802		$	5.1		6.2		$	50,465,826
	Outstanding at April 1, 2014	5,939,710
	Granted during period	155,975		$	8.81
	Exercised during period	-39,709		$	2.51
	Expired during period	-255		$	6.69
	Forfeited during period	-100,464		$	15.08
	Outstanding at June 30, 2014	5,955,257		$	7.39		7.4		$	7,864,108
	Exercisable at June 30, 2014	2,985,828		$	5.76		6.2		$	6,175,294

Significant_Accounting_Policie3

Significant Accounting Policies (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Numerator:	'	'	'	'
Net income	$22,356,642	($8,227,476)	$19,215,183	($12,089,147)
Weighted-average common shares outstanding:	'	'	'	'
Basic (in shares)	41,398,251	35,991,402	38,810,473	35,961,002
Diluted (in shares)	43,196,754	35,991,402	40,861,295	35,961,002
Net income (loss) per share:	'	'	'	'
Basic (in dollars per share)	$0.54	($0.23)	$0.50	($0.34)
Diluted (in dollars per share)	$0.52	($0.23)	$0.47	($0.34)

Significant_Accounting_Policie4

Significant Accounting Policies (Details 1)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Potential Common Stock Equivalents, Outstanding	6,453,846	5,534,777
Shares to be purchased under the ESPP [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Potential Common Stock Equivalents, Outstanding	2,092	0
Outstanding common stock options [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Potential Common Stock Equivalents, Outstanding	5,955,257	5,128,059
Outstanding PRSUs [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Potential Common Stock Equivalents, Outstanding	270,386	272,750
Outstanding RSUs [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Potential Common Stock Equivalents, Outstanding	191,464	0
Outstanding warrants [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Potential Common Stock Equivalents, Outstanding	34,647	133,968

Significant_Accounting_Policie5

Significant Accounting Policies (Details 2)	3 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2014
Total Weighted Average Outstanding Common Stock equivalents	1,798,503	2,050,822
Outstanding RSUs [Member]	'	'
Total Weighted Average Outstanding Common Stock equivalents	16,035	28,242
Outstanding warrants [Member]	'	'
Total Weighted Average Outstanding Common Stock equivalents	9,728	12,822
Outstanding common stock options [Member]	'	'
Total Weighted Average Outstanding Common Stock equivalents	1,771,695	2,008,581
Shares to be purchased under the ESPP [Member]	'	'
Total Weighted Average Outstanding Common Stock equivalents	1,045	1,177

Significant_Accounting_Policie6

Significant Accounting Policies (Details Textual) (Research and Development Arrangement [Member], USD $)	Jun. 30, 2014
In Millions, unless otherwise specified
Research and Development Arrangement [Member]	'
Significant Accounting Policies [Line Items]	'
Prepaid Expense and Other Assets	$0.60

Other_Comprehensive_Income_Los2

Other Comprehensive Income (Loss) (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Other Comprehensive Income Loss [Line Items]	'	'	'	'
Foreign Currency Translation Losses, Beginning balance	($11,306)	($4,381)	($11,816)	($5,011)
Foreign Currency Translation Losses, Unrealized loss	-29,010	-21,880	-28,500	-21,250
Foreign Currency Translation Losses, Net amount reclassified to net income (loss)	0	0	0	0
Foreign Currency Translation Losses, Other comprehensive loss	-29,010	-21,880	-28,500	-21,250
Foreign Currency Translation Losses, Ending balance	-40,316	-26,261	-40,316	-26,261
Unrealized Net Gains (Losses) on Securities, Beginning balance	59,650	37,546	68,507	77,760
Unrealized Net Gains (Losses) on Securities, Unrealized loss	-57,521	-98,412	-66,378	-134,671
Unrealized Net Gains (Losses) on Securities, Net amount reclassified to net income (loss)	0	-425	0	-4,380
Unrealized Net Gains (Losses) on Securities, Other comprehensive loss	-57,521	-98,837	-66,378	-139,051
Unrealized Net Gains (Losses) on Securities, Ending balance	2,129	-61,291	2,129	-61,291
Accumulated Other Comprehensive Income (Loss), Beginning balance	48,344	33,165	56,691	72,749
Accumulated Other Comprehensive Income (Loss), Unrealized loss	-86,531	-120,292	-94,878	-155,921
Accumulated Other Comprehensive Income (Loss), Net amount reclassified to net income (loss)	0	-425	0	-4,380
Accumulated Other Comprehensive Income (Loss), Income comprehensive loss	-86,531	-120,717	-94,878	-160,301
Accumulated Other Comprehensive Income (Loss), Ending balance	($38,187)	($87,552)	($38,187)	($87,552)

Investments_Details

Investments (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2012
Cash	'	'	'	'
Cash	$10,765,408	$7,887,502	'	'
Cash equivalents	'	'	'	'
Money market funds	20,803,095	44,959,438	'	'
Cash and cash equivalents	31,568,503	52,846,940	64,216,440	33,996,866
Short-term investments (due within 1 year)	'	'	'	'
Short-term investments	89,533,740	70,434,148	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total long-term investments	98,097,613	25,571,659	'	'
US Treasury Securities [Member]	'	'	'	'
Short-term investments (due within 1 year)	'	'	'	'
Short-term investments	5,000,800	5,013,850	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total long-term investments	25,672,825	'	'	'
US Government Agencies Debt Securities [Member]	'	'	'	'
Short-term investments (due within 1 year)	'	'	'	'
Short-term investments	48,704,565	33,609,886	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total long-term investments	43,012,895	14,821,065	'	'
Corporate Debt Securities [Member]	'	'	'	'
Short-term investments (due within 1 year)	'	'	'	'
Short-term investments	35,828,375	31,810,412	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total long-term investments	29,411,893	10,750,594	'	'
Fair Value, Inputs, Level 1 [Member]	'	'	'	'
Cash	'	'	'	'
Cash	10,765,408	7,887,502	'	'
Cash equivalents	'	'	'	'
Money market funds	20,803,095	44,959,438	'	'
Cash and cash equivalents	31,568,503	52,846,940	'	'
Short-term investments (due within 1 year)	'	'	'	'
Short-term investments	53,705,365	38,623,736	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total long-term investments	68,685,720	14,821,065	'	'
Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]	'	'	'	'
Short-term investments (due within 1 year)	'	'	'	'
Short-term investments	5,000,800	5,013,850	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total long-term investments	25,672,825	'	'	'
Fair Value, Inputs, Level 1 [Member] | US Government Agencies Debt Securities [Member]	'	'	'	'
Short-term investments (due within 1 year)	'	'	'	'
Short-term investments	48,704,565	33,609,886	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total long-term investments	43,012,895	14,821,065	'	'
Fair Value, Inputs, Level 1 [Member] | Corporate Debt Securities [Member]	'	'	'	'
Short-term investments (due within 1 year)	'	'	'	'
Short-term investments	0	0	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total long-term investments	0	0	'	'
Fair Value, Inputs, Level 2 [Member]	'	'	'	'
Cash	'	'	'	'
Cash	0	0	'	'
Cash equivalents	'	'	'	'
Money market funds	0	0	'	'
Cash and cash equivalents	0	0	'	'
Short-term investments (due within 1 year)	'	'	'	'
Short-term investments	35,828,375	31,810,412	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total long-term investments	29,411,893	10,750,594	'	'
Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]	'	'	'	'
Short-term investments (due within 1 year)	'	'	'	'
Short-term investments	0	0	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total long-term investments	0	'	'	'
Fair Value, Inputs, Level 2 [Member] | US Government Agencies Debt Securities [Member]	'	'	'	'
Short-term investments (due within 1 year)	'	'	'	'
Short-term investments	0	0	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total long-term investments	0	0	'	'
Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities [Member]	'	'	'	'
Short-term investments (due within 1 year)	'	'	'	'
Short-term investments	35,828,375	31,810,412	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total long-term investments	29,411,893	10,750,594	'	'
Cost [Member]	'	'	'	'
Cash	'	'	'	'
Cash	10,765,408	7,887,502	'	'
Cash equivalents	'	'	'	'
Money market funds	20,803,095	44,959,438	'	'
Cash and cash equivalents	31,568,503	52,846,940	'	'
Short-term investments (due within 1 year)	'	'	'	'
Short-term investments	89,507,932	70,396,681	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total long-term investments	98,121,292	25,551,349	'	'
Cost [Member] | US Treasury Securities [Member]	'	'	'	'
Short-term investments (due within 1 year)	'	'	'	'
Short-term investments	5,000,246	5,009,194	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total long-term investments	25,650,619	'	'	'
Cost [Member] | US Government Agencies Debt Securities [Member]	'	'	'	'
Short-term investments (due within 1 year)	'	'	'	'
Short-term investments	48,680,354	33,598,370	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total long-term investments	43,048,665	14,807,642	'	'
Cost [Member] | Corporate Debt Securities [Member]	'	'	'	'
Short-term investments (due within 1 year)	'	'	'	'
Short-term investments	35,827,332	31,789,117	'	'
Long-term investments (due after 1 year through 2 years)	'	'	'	'
Total long-term investments	$29,422,008	$10,743,707	'	'

Investments_Details_Textual

Investments (Details Textual) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Schedule of Trading Securities and Other Trading Assets [Line Items]	'	'
Unrealized Gain on Securities	$80,174	$20,410
Unrealized Loss on Securities	$78,045	$81,701

Collaborations_Details_Textual

Collaborations (Details Textual) (USD $)	1 Months Ended	3 Months Ended	6 Months Ended	3 Months Ended	1 Months Ended	6 Months Ended	1 Months Ended
In Millions, unless otherwise specified	Apr. 30, 2012	Jun. 30, 2014	Jun. 30, 2014	Sep. 30, 2014	Aug. 31, 2013	Jun. 30, 2014	Apr. 30, 2012
				Scenario, Forecast [Member]	NMP [Member]	NMP [Member]	Non Substantive Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'	'	'	'
Milestone Payments	'	$5	$5	'	'	'	'
Payments to Acquire in Process Research and Development	120	'	'	'	'	'	'
Non-refundable Upfront Payments Received	120	'	'	'	1	'	5
Collaboration Revenue	'	49.2	66.4	2.2	'	'	'
Deferred Revenue	'	31.1	31.1	'	'	1	'
Potential Milestone Payments	'	'	'	'	'	4.5	'
Licenses Revenue	'	39	52.7	'	'	'	'
License and Services Revenue	'	$10.20	$13.70	'	'	'	'

Stockholders_Equity_Deficit_De

Stockholders' Equity (Deficit) (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'	'	'
Weighted-average volatility	107.00%	102.00%	102.80%	101.20%
Risk-free interest rate	2.34%	1.78%	1.98%	1.19%
Weighted-average expected life (in years)	'8 years 10 months 24 days	'7 years 10 months 24 days	'6 years 8 months 12 days	'6 years 7 months 6 days
Dividend yield	0.00%	0.00%	0.00%	0.00%

Stockholders_Equity_Deficit_De1

Stockholders' Equity (Deficit) (Details 1) (Stock Option [Member], USD $)	3 Months Ended
	Jun. 30, 2014	Mar. 31, 2014
Stock Option [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options, Outstanding, Beginning Balance	5,939,710	5,246,465
Options, Granted during year	155,975	856,261
Options, Exercised during year	-39,709	-147,091
Options, Expired during year	-255	0
Options, Forfeited during year	-100,464	-15,925
Options, Outstanding, Ending Balance	5,955,257	5,939,710
Options, Exercisable	2,985,828	2,697,802
Weighted Average Exercise Price, Outstanding, Beginning Balance	$7.45	$6.76
Weighted Average Exercise Price, Granted during year	$8.81	$11.13
Weighted Average Exercise Price, Exercised during year	$2.51	$3.27
Weighted average Exercise Price, Expired during year	$6.69	$0
Weighted Average Exercise Price, Forfeited during year	$15.08	$16.42
Weighted Average Exercise Price, Outstanding, Ending Balance	$7.39	$7.45
Weighted Average Exercise Price, Exercisable	$5.76	$5.10
Weighted Average Remaining Contractual Term, Outstanding, Ending Balance	'7 years 4 months 24 days	'7 years 7 months 6 days
Weighted Average Remaining Contractual Term, Exercisable	'6 years 2 months 12 days	'6 years 2 months 12 days
Aggregate Intrinsic Value, Outstanding, Ending Balance	$7,864,108	$97,181,600
Aggregate Intrinsic Value, Exercisable	$6,175,294	$50,465,826

Stockholders_Equity_Deficit_De2

Stockholders' Equity (Deficit) (Details Textual) (USD $)	1 Months Ended	3 Months Ended	6 Months Ended
	Apr. 02, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Stockholders' Equity Deficit [Line Items]	'	'	'	'	'
Common Stock, Shares Authorized	'	100,000,000	100,000,000	'	100,000,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	'	$18,400,000	$18,400,000	'	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'	'	'1 year 9 months 18 days	'	'
Stock Issued During Period, Shares, New Issues	5,175,000	'	'	'	'
Proceeds from Issuance of Common Stock	101,900,000	'	101,904,977	0	'
Stock Issued During Period, Shares, Employee Stock Purchase Plans	'	32,168	'	'	'
Restricted Stock Units (RSUs) [Member]	'	'	'	'	'
Stockholders' Equity Deficit [Line Items]	'	'	'	'	'
Percentage of Historical Forfeiture	'	'	6.49%	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	'	270,386	270,386	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Vesting Term, Description	'	'	'PRSUs will vest fifty percent based on the performance condition of commercial approval and fifty percent one year thereafter	'	'
Employee Benefits and Share-based Compensation	'	'	2,700,000	'	'
Equity Incentive Plan 2010 [Member]	'	'	'	'	'
Stockholders' Equity Deficit [Line Items]	'	'	'	'	'
Common Stock, Shares Authorized	'	8,071,563	8,071,563	'	6,625,563
Equity Incentive Plan 2010 [Member] | Restricted Stock Units (RSUs) [Member]	'	'	'	'	'
Stockholders' Equity Deficit [Line Items]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	'	191,464	191,464	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Vesting Term, Description	'	'	'RSUs are service-based awards that will vest and be paid in four equal installments annually beginning in February 2015	'	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	'	$11.11	$11.11	'	'
Allocated Share-based Compensation Expense	'	'	$1,900,000	'	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	'	'	'2 years 3 months 18 days	'	'
Employee Stock Purchase Plan [Member]	'	'	'	'	'
Stockholders' Equity Deficit [Line Items]	'	'	'	'	'
Common Stock, Shares Authorized	'	590,612	590,612	'	622,780
Stock Issued During Period, Shares, Employee Stock Purchase Plans	'	'	32,168	'	'
Share Price	'	$5.94	$5.94	'	'

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	Jun. 30, 2014
In Millions, unless otherwise specified
For 2014 [Member]	'
Operating Loss Carryforwards [Line Items]	'
Operating Loss Carryforwards	$133.20
For 2015 [Member]	'
Operating Loss Carryforwards [Line Items]	'
Operating Loss Carryforwards	39
For 2016 [Member]	'
Operating Loss Carryforwards [Line Items]	'
Operating Loss Carryforwards	29.7
For 2017 [Member]	'
Operating Loss Carryforwards [Line Items]	'
Operating Loss Carryforwards	$16.80

Restructuring_Costs_Details_Te

Restructuring Costs (Details Textual) (USD $)	3 Months Ended	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2014
Restructuring Cost and Reserve [Line Items]	'	'
Restructuring and Related Cost, Expected Cost	$4.80	$4.80
Employee Severance [Member]	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Restructuring Costs	1.3	1.3
Restructuring and Related Cost, Expected Cost	0.7	0.7
Contract Termination [Member]	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Restructuring and Related Cost, Expected Cost	0.4	0.4
Proceed Trial Termination [Member]	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Restructuring and Related Cost, Expected Cost	$4.80	$4.80